Paolo Caimi, MD – Hematopoietic/Lymphoid Cancer

Access Program Information

This clinical trial studies the use of a second infusion of donor hematopoietic cells that
have had removal of T cells for the treatment of engraftment failure after a first
hematopoietic stem cell transplant.

Hematopoietic cell transplants from donors can be complicated by complete or incomplete
failure of recovery of blood counts. This results in frequent needs for transfusions and
other methods to maintain blood counts at acceptable levels. One way of improving the blood
counts in the recipient is to give a “booster” dose of cells from the donor, but this is
associated with increased risk of an immune reaction from the donor cells against the
recipient cells. To decrease this risk, it is possible to decrease the amount of T cells,
responsible for this type of immune reaction. These cells are removed by a special handling
of the graft, which allows to remove the cells directly or indirectly (by selecting other
cells to “stay” in the graft”).

Rare Disease: